Allspring Global Investments Holdings LLC Increases Holdings in Haemonetics Corporation (NYSE:HAE)

Allspring Global Investments Holdings LLC increased its stake in Haemonetics Corporation (NYSE:HAE - Free Report) by 20.6% in the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 966,167 shares of the medical instruments supplier's stock after acquiring an additional 165,118 shares during the quarter. Allspring Global Investments Holdings LLC owned 1.92% of Haemonetics worth $60,888,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also bought and sold shares of the stock. Arizona State Retirement System lifted its stake in shares of Haemonetics by 1.2% in the fourth quarter. Arizona State Retirement System now owns 14,853 shares of the medical instruments supplier's stock valued at $1,160,000 after buying an additional 181 shares in the last quarter. CWC Advisors LLC. increased its holdings in Haemonetics by 7.4% during the 4th quarter. CWC Advisors LLC. now owns 3,083 shares of the medical instruments supplier's stock worth $241,000 after purchasing an additional 212 shares in the last quarter. Vise Technologies Inc. increased its holdings in Haemonetics by 8.7% during the 4th quarter. Vise Technologies Inc. now owns 2,825 shares of the medical instruments supplier's stock worth $221,000 after purchasing an additional 225 shares in the last quarter. Parkside Financial Bank & Trust lifted its holdings in shares of Haemonetics by 25.6% in the fourth quarter. Parkside Financial Bank & Trust now owns 1,176 shares of the medical instruments supplier's stock valued at $92,000 after purchasing an additional 240 shares in the last quarter. Finally, HighTower Advisors LLC raised its position in Haemonetics by 7.8% in the 4th quarter. HighTower Advisors LLC now owns 3,353 shares of the medical instruments supplier's stock valued at $262,000 after buying an additional 244 shares during the last quarter. 99.67% of the stock is owned by institutional investors.

Haemonetics Trading Up 0.8%

Shares of HAE traded up $0.61 during trading hours on Thursday, hitting $76.85. The company had a trading volume of 249,556 shares, compared to its average volume of 669,827. Haemonetics Corporation has a 52-week low of $55.30 and a 52-week high of $94.99. The company has a quick ratio of 0.99, a current ratio of 1.62 and a debt-to-equity ratio of 1.12. The stock's 50 day moving average price is $68.82 and its 200 day moving average price is $68.14. The firm has a market cap of $3.69 billion, a P/E ratio of 23.22, a P/E/G ratio of 1.24 and a beta of 0.39.

Haemonetics (NYSE:HAE - Get Free Report) last posted its quarterly earnings results on Thursday, May 8th. The medical instruments supplier reported $1.24 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.22 by $0.02. Haemonetics had a return on equity of 26.37% and a net margin of 12.32%. The business had revenue of $330.60 million for the quarter, compared to analyst estimates of $329.38 million. During the same period last year, the company earned $0.90 EPS. Haemonetics's revenue for the quarter was down 3.5% compared to the same quarter last year. On average, research analysts predict that Haemonetics Corporation will post 4.55 EPS for the current year.

Wall Street Analyst Weigh In

Several brokerages have recently commented on HAE. Robert W. Baird began coverage on shares of Haemonetics in a report on Thursday, June 26th. They issued an "outperform" rating and a $87.00 target price for the company. Needham & Company LLC cut their price target on shares of Haemonetics from $104.00 to $84.00 and set a "buy" rating on the stock in a report on Thursday, May 8th. JMP Securities restated a "market outperform" rating and issued a $100.00 target price on shares of Haemonetics in a research note on Tuesday, May 20th. Raymond James Financial restated a "strong-buy" rating and issued a $105.00 price objective (down from $115.00) on shares of Haemonetics in a research note on Friday, May 9th. Finally, Baird R W upgraded shares of Haemonetics to a "strong-buy" rating in a research report on Wednesday, June 25th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating, seven have issued a buy rating and two have given a strong buy rating to the company's stock. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus price target of $96.80.

About Haemonetics

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.